Skip to main content

Table 2 Adverse events in ≥2 patients

From: MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a Phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments

  SAD Stage MD Stage
No. (%) Patients Placebo
(n= 6) 		All Active
(n= 24) 		Placebo
(n= 7) 		1.5 mg/kg (SC) (n= 12) 3.5 mg/kg (SC) (n= 12) 5.0 mg/kg (IV)(n= 5) All Active(n= 29)
Adverse Events        
   Any event 1 (17) 6 (25) 0 (0) 1 (8) 3 (25) 1 (20) 5 (17)
   Nausea 0 (0) 2 (8) 0 (0) 0 (0) 1 (8) 0 (0) 1 (3)
   Flank pain 0 (0) 2 (8) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
   Fatigue 0 (0) 0 (0) 0 (0) 1 (8) 1 (8) 0 (0) 2 (7)
   Pruritis 0 (0) 0 (0) 0 (0) 0 (0) 1 (8) 1 (20) 2 (7)
   Rash 0 (0) 0 (0) 0 (0) 0 (0) 1 (8) 1 (20) 2 (7)
Serious Adverse Events        
Any event 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
  1. IV, intravenous; MD, multiple dose; SAD, single ascending dose; SC, subcutaneous.
  2. *Adverse events determined by investigators to be related to MTRX1011A by preferred term in ≥ 2 patients.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us